| Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients I Rudberg, B Mohebi, M Hermann, H Refsum, E Molden Clinical Pharmacology & Therapeutics 83 (2), 322-327, 2008 | 300 | 2008 |
| Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several‐fold in patients with atorvastatin‐induced myopathy M Hermann, MP Bogsrud, E Molden, A Åsberg, BU Mohebi, L Ose, ... Clinical Pharmacology & Therapeutics 79 (6), 532-539, 2006 | 167 | 2006 |
| Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus WPD Lemahieu, M Hermann, A Asberg, K Verbeke, H Holdaas, ... American Journal of Transplantation 5 (9), 2236-2243, 2005 | 164 | 2005 |
| Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC–tandem MS M Hermann, H Christensen, JLE Reubsaet Analytical and bioanalytical chemistry 382, 1242-1249, 2005 | 160 | 2005 |
| Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients I Rudberg, M Hermann, H Refsum, E Molden European journal of clinical pharmacology 64, 1181-1188, 2008 | 104 | 2008 |
| Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5 GV Bakken, I Rudberg, H Christensen, E Molden, H Refsum, M Hermann Drug metabolism and disposition 37 (2), 254-258, 2009 | 102 | 2009 |
| Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole M Hendset, M Hermann, H Lunde, H Refsum, E Molden European journal of clinical pharmacology 63, 1147-1151, 2007 | 96 | 2007 |
| Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole RB Waade, H Christensen, I Rudberg, H Refsum, M Hermann Therapeutic drug monitoring 31 (2), 233-238, 2009 | 91 | 2009 |
| Substantially elevated levels of atorvastatin and metabolites in cyclosporine‐treated renal transplant recipients M Hermann, A Åsberg, H Christensen, H Holdaas, A Hartmann, ... Clinical Pharmacology & Therapeutics 76 (4), 388-391, 2004 | 90 | 2004 |
| Immunological response as a source to variability in drug metabolism and transport H Christensen, M Hermann Frontiers in pharmacology 3, 8, 2012 | 86 | 2012 |
| Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6* 3,* 4 or* 5 allele M Hermann, M Hendset, K Fosaas, M Hjerpset, H Refsum European journal of clinical pharmacology 64, 483-487, 2008 | 73 | 2008 |
| Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone M Hendset, E Molden, H Refsum, M Hermann Journal of clinical psychopharmacology 29 (6), 537-541, 2009 | 59 | 2009 |
| Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups RB Waade, M Hermann, HL Moe, E Molden European journal of clinical pharmacology 70, 933-940, 2014 | 58 | 2014 |
| Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients GV Bakken, I Rudberg, E Molden, H Refsum, M Hermann Therapeutic drug monitoring 33 (2), 222-226, 2011 | 56 | 2011 |
| Serum concentrations of antidepressants in the elderly RB Waade, E Molden, H Refsum, M Hermann Therapeutic drug monitoring 34 (1), 25-30, 2012 | 54 | 2012 |
| High tacrolimus clearance is a risk factor for acute rejection in the early phase after renal transplantation EJ Egeland, I Robertsen, M Hermann, K Midtvedt, E Størset, ... Transplantation 101 (8), e273-e279, 2017 | 52 | 2017 |
| Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro GV Bakken, E Molden, K Knutsen, N Lunder, M Hermann Drug metabolism and disposition 40 (9), 1778-1784, 2012 | 52 | 2012 |
| Intake of grapefruit juice alters the metabolic pattern of cyclosporin A in renal transplant recipients. M Hermann, A Asberg, JL Reubsaet, S Sather, KJ Berg, H Christensen International journal of clinical pharmacology and therapeutics 40 (10), 451-456, 2002 | 42 | 2002 |
| COVID-19 effects on the kidney K Amann, P Boor, T Wiech, J Singh, E Vonbrunn, A Knöll, M Hermann, ... Der Pathologe 42 (Suppl 1), 76-80, 2021 | 35* | 2021 |
| Serum concentrations of risperidone and aripiprazole in subgroups encoding CYP2D6 intermediate metabolizer phenotype M Hendset, E Molden, M Knape, M Hermann Therapeutic drug monitoring 36 (1), 80-85, 2014 | 35 | 2014 |
